Recombinant Mouse SLAMF7/CD319 protein (rFc Tag)(HPLC verified)

种属

Mouse

纯度

>90 %, SDS-PAGE
>90 %, SEC-HPLC

标签

rFc Tag

生物活性

未测试

Cat no : Eg2672

Print datasheet

Synonyms

CD319, Leukocyte cell-surface antigen, Novel Ly9, SLAM family member 7, Slamf7



产品信息

纯度 >90 %, SDS-PAGE
>90 %, SEC-HPLC
内毒素 <0.1 EU/μg protein, LAL method
生物活性
Not tested
来源 HEK293-derived Mouse SLAMF7 protein Ser23-Gly224 (Accession# Q8BHK6-1) with a rabbit IgG Fc tag at the C-terminus.
基因ID 75345
蛋白编号 Q8BHK6-1
预测分子量 48.3 kDa
SDS-PAGE 50-65 kDa, reducing (R) conditions
组分 Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
复溶 Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
储存条件
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
运输条件 The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

背景信息

Signaling lymphocyte activation molecule (SLAM) family receptors is a group of type I transmembrane receptors belonging to the immunoglobulin superfamily. The SLAM family contains nine members that contain an extracellular segment comprising two or four Ig-like domains (V-like variable and C2-like constant), a transmembrane region and a cytoplasmic tail. They are involved in various physiological and pathological processes, including the regulation of immunological responses and the route of viral entry. SLAMF7, also known as CS1, CRACC or CD319, is expressed on NK cells, CD8+ T lymphocytes, B lymphocytes, and mature dendritic cells. It exerts both activating and inhibitory effects depending on the expression status of SAP or EAT-2. SLAMF7 is overexpressed in multiple myeloma and makes it a target for immunotherapy.

参考文献:

1.Farhangnia P, et al. (2023) Front Immunol. 11;14:1174138. 2.Fouquet G, et al. (2018) Oncotarget. 26;9(22):16248-16262. 3.Malaer JD, et al. (2017) Am J Cancer Res. 1;7(8):1637-1641.